On June 20th, Gelonhui reported that Sanyuan Biology (301206.SZ) stated on the investor interaction platform that the company's Tagatose is still in the research and development stage and has not yet been sold to the public in 2023. The laboratory technology has been successfully connected and the company is currently committed to solving the cost control issues in large-scale production, with the goal of reducing costs to a level that can be widely used by the csi sws food & beverage index. The company is actively organizing technological research and development, striving to achieve technological implementation as soon as possible.
三元生物(301206.SZ)：公司塔格糖仍处于研发阶段，2023年尚未对外销售
Sanyuan Biology (301206.SZ): Tagatose of the company is still in the research and development stage and has not yet been sold externally in 2023.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.